CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：NK Cell Immaturity and NKp30 Expression Positively Correlate with Clinical Outcome in Multiple Myeloma Patients from the IFM2009 Clinical Trial.
NK Cell Immaturity and NKp30 Expression Positively Correlate with Clinical Outcome in Multiple Myeloma Patients from the IFM2009 Clinical Trial.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多发性骨髓瘤（MM）是一种肿瘤性浆细胞增殖性疾病，目前仍无法治愈。自然杀伤（NK）细胞能够在体外识别并杀伤MM细胞。然而，既往文献提示MM患者中NK细胞功能存在异常。为了进一步评估这一点，我们利用IFM2009试验及其相关样本，采用多参数流式细胞术监测MM诊断时骨髓样本中NK细胞的表型。我们的结果显示，MM患者中NK细胞频率增加。对NK细胞表型的详细分析显示，MM患者NK细胞中终末成熟标志物如KLRG1或CD57的表达降低，而CD56 bright/组织驻留标志物的表达增加。随着患者ISS评分升高，这些改变的程度更加显著。最后，良好的临床演变一方面与NK细胞不成熟相关，另一方面与NKp30水平相关，NKp30是一种在未成熟NK细胞中表达更多的受体。总之，这些数据表明未成熟和驻留NK细胞特别参与抗骨髓瘤反应，尤其是通过NKp30，这可能为未来的治疗策略铺平道路。
Multiple myeloma (MM) is a proliferation of tumoral plasma cells that is still incurable. Natural killer (NK) cells can recognize and kill MM cells in vitro.
However, previous literature suggests an alteration of NK cell function in MM patients. To further evaluate this point, we used multi-parametric flow cytometry to monitor NK cell phenotype in bone marrow samples at diagnosis of MM, taking advantage of the IFM2009 trial and associated samples.
Our results show an increase in the frequency of NK cells in MM patients. A detailed analysis of NK cell phenotype showed a decreased expression of terminal maturation markers such as KLRG1 or CD57 and an increased expression of CD56 bright /tissue resident markers among NK cells from MM patients. The extent of these alterations is even more pronounced as the ISS score increases in patients.
Finally, a favorable clinical evolution correlates with NK cell immaturity, on the one hand, and with the level of NKp30, a receptor more expressed in immature NK cells on the other hand. Altogether, these data suggest that immature and resident NK cells are particularly involved in the anti-myeloma response, notably via NKp30, which could pave the way for future therapeutic strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
